Accure Therapeutics signs licensing agreement with Oculis

Mar 3, 2022

We are pleased to announce that our portfolio company Accure Therapeutics signed an exclusive worldwide licensing agreement with Oculis to develop and commercialise a potentially disease modifying therapy to protect and prevent damage to the optic nerve and retina. LifeLink is proud of the entire Accure team for bringing this deal together and we look forward to supporting the company in future developments.


Feel free to share on: